| KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. | None |
| Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. | None |
| [Modulation of activated oncogene c-kit expression with RNA-interference]. | None |
| Frequency elevation of the KIT proto-oncogene exon 8 deletion and point mutations in AML cases. | None |
| KIT proto-oncogene exon 8 deletions at codon 419 are highly frequent in acute myeloid leukaemia with inv(16) in Indian population. | None |
| Data show that in contrast to the oncogenic KITD816V, TET2 mutation statistically associates with aggressive forms of the disease. | None |
| Downregulation of Fas activity rescues early onset of diabetes in c-Kit(Wv/+) mice. | None |
| The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells. | None |
| The KIT-D816V mutation is a mild oncogenic event that is sufficient to confer partial transforming properties. | None |
| [C-kit and other receptor tyrosine kinases play a crucial role in oncogenic signaling and drug-resistance]. | None |
| Identification of the c-kit gene mutations in biopsy tissues of mammary gland carcinoma tumor. | None |
| CDC37 is a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors | None |
| Data indicate that PI3-kinase p110delta is phosphorylated by proto-oncogene c-Kit/D816V at Y524 and S1039. | None |
| Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. | None |
| Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. | None |
| Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. | None |
| Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. | None |
| The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. | None |
| Germline KIT mutations associated with mastocytosis drive a well-differentiated mast cell phenotype distinct to that of somatic KIT D816V disease, the oncogenic potential of which might be influenced by SCF and selective KIT splicing | None |
| The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. | None |